In today's corporate landscape, competition has become a ubiquitous phenomenonWe see it in e-commerce, the automotive sector, and now even companies are engaging in what one might describe as a "dividend war." Since the onset of 2023, China's regulatory bodies have been nudging publicly listed companies towards more generous dividend distributions, aimed at enhancing investor returnsThe response is striking, with over 270 companies projected to issue dividends in their third-quarter reports for 2024.

Among the leaders in this burgeoning dividend scene are notable companies like Guizhou Maotai, Wuliangye, Muyuan Food, Yunnan Baiyao, and Mindray Medical, each boasting a staggering payout exceeding 2 billion RMB in their third-quarter reportsYunnan Baiyao, for instance, stands out with a dividend payout ratio of 50% and a dividend yield of 4.23% as of 2024's third-quarter reportThis company has distributed an impressive cumulative dividend of 26.6 billion RMB since its listing, earning it the moniker of "dividend machine."

The general wisdom is that higher dividends indicate better profitabilityWhile brands like Guizhou Maotai and Wuliangye are often likened to China’s equivalent of Coca-Cola for their market dominance and brand recognition, Yunnan Baiyao, along with companies like Mindray and China Resources Sanjiu, demonstrates remarkable resilience in the pharmaceutical sectorHowever, this raises an interesting question for investors: has the performance of pharmaceutical companies been as robust as expected in recent years?

In fact, a thorough examination of the pharmaceutical sector reveals a mixed bagIn the first three quarters of 2024, the sector’s overall revenue dipped by 0.75%, while net profits claimed a more significant decrease of 7.98%. This reduction might seem alarming at first glance, but it actually represents a marked improvement over the previous yearSo, how has Yunnan Baiyao managed to maintain its high dividend payouts despite these trends?

To unravel this mystery, one must first consider Yunnan Baiyao’s earnings trajectory

Advertisements

Since 2020, the company has consistently reported revenue growth, and when excluding non-core business investments, its net profit growth has been even more encouraging, boasting a compound annual growth rate of 13.24% from 2020 to 2023, with a 10.68% increase in the first three quarters of 2024 aloneAdditionally, Yunnan Baiyao's strong cash generation capabilities lend a robust backing to its dividend policy.

On the one hand, the company has maintained a relatively high net cash ratio, especially since 2021, hovering around 1, which highlights its improved operational qualityOn the other hand, Yunnan Baiyao has experienced a net cash outflow from financing activities for the past seven yearsInstead, operational cash flow has emerged as the primary source of funds, with the company reportedly earning about 4 billion RMB annually, surpassing more than 90% of its peers in the industry.

This showcases that Yunnan Baiyao is not only excelling in financial performance but also possesses a remarkable ability to generate cash, thus illustrating its significant operational resilience—a quality that distinctly separates it from competitors like Hengrui Medicine and Pian Zai Huang.

But why is Yunnan Baiyao so formidable in its field?

Firstly, the company boasts a unique "moat." Many consumers may recognize Yunnan Baiyao primarily for its toothpaste line, which has maintained industry dominance with a market share of 24.6% in 2023. However, as a traditional Chinese medicine enterprise, Yunnan Baiyao's core competitive edge lies in its proprietary product line, particularly its Baiyao series.

The Baiyao product range is steeped in history, built upon a state-level secret formula that has been kept under wraps for decades—this level of secrecy provides a protective buffer that is even more secure than a limited-period patent, thus shielding the company from competitive threats and risks commonly found in consumer marketsNotably, the infusion of this formula into its toothpaste creates a product that is extremely difficult to replicate, further securing the company’s multiple business lines.

Secondly, Yunnan Baiyao's products exhibit strong resistance to market cycles

Advertisements

Taking a comparative perspective with Pian Zai Huang, which also relies on a closely guarded formula yet faced sales stagnation due to price hikes, Yunnan Baiyao continues to experience growthIts industrial product revenue grew impressively from 2 billion RMB in 2008 to over 13.74 billion RMB by 2023—an increase of approximately 6.5 times over 15 yearsWhile Yunnan Baiyao may not possess strong pricing power, it is simultaneously insulated from raw material cost pressures, indicating a product market that is expanding rather than contracting.

There is also noteworthy growth potential for the toothpaste segment alone; the market has surged from less than 20 billion RMB in 2013 to around 30 billion RMB in 2023. Furthermore, Baiyao products which primarily target bleeding, pain relief, and swelling reduction align perfectly with the market expansion trend of traditional Chinese medicine.

But what about Yunnan Baiyao's growth prospects moving forward?

This can be considered from two primary angles:

First, the cultivation of ancillary growth curves around pharmaceuticals and health products appears promisingHistorically, predictability within this core business can be elusive, yet signs point towards solid growth potential, especially when assessing Yunnan Baiyao’s long-standing market presence and competitive advantages.

Moreover, the company seems committed to diversifying its product lines by introducing new traditional Chinese medicines, supplement products, anti-hair-loss sanitary products, and herbal materials, thus augmenting its offeringsFor example, in the first half of 2024, sales of Pudilan Anti-inflammatory Tablets surpassed the one-hundred-million mark, positioning Yunnan Baiyao for substantial growth considering comparable products from competitors like Jichuan Pharmaceutical can reach annual sales of up to 2 billion RMB.

Second, improving profitability could lead to unexpected growth outcomesYunnan Baiyao’s business segments encompass both industrial and pharmaceutical commercial ventures, specifically focusing on the logistics surrounding drug distribution.

However, 2024's market conditions, shaped by the pharmaceutical and consumer landscapes, have adversely affected sales performances in its pharmaceutical commercial and toothpaste sectors

Advertisements

Advertisements

Advertisements